Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Although Kymriah's approval represents a landmark for chimeric antigen receptor T-cell (CAR-T) therapy in B-cell malignancies, solid tumors remain a formidable challenge.
How to develop a new vaccine or therapeutic modality in a skeptical environment, with little biotech experience, limited resources and limited capital.
The Supreme Court's decision in Sandoz v. Amgen introduces uncertainty into provisions that many viewed as necessary and enforceable, but its impact may ultimately be modest.